CG Oncology Inc.
Rating
Updated: Aug 28, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s prod...
Latest News
2 days ago · defenseworld.net
Insider Selling: CG Oncology (NASDAQ:CGON) Director Sells $72,980.00 in StockCG Oncology, Inc. (NASDAQ: CGON - Get Free Report) Director Leonard Post sold 1,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $72.98, for a total transaction of $72,980.00. Following the completion of the sale, the director directly owned 1,000 shares
8 days ago · seekingalpha.com
CG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptCG Oncology, Inc. (CGON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
20 days ago · globenewswire.com
CG Oncology to Present at Upcoming Investor Conferences in SeptemberDALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive Officer, will participate in fireside chat presentations at the Cantor Fitzgerald and Morgan Stanley Global Healthcare Conferences in New York City this month. The details of the upcoming events are as follows:
1 month ago · prnewswire.com
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law FirmNEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of CG Oncology, Inc. ( NASDAQ : CGON) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
1 month ago · seekingalpha.com
CG Oncology: Circling Back After Huge RallyCG Oncology is advancing cretositimogene grenadenorepvec (cret) for NMIBC, showing strong efficacy and best-in-class safety versus competitors. Cret achieved a 75% anytime CR, 46% 12-month CR, and 42% 24-month CR in BOND-003 Cohort C, with no Grade 3+ adverse events. Rolling BLA for cret in HR BCG-unresponsive NMIBC is expected to complete in 4Q26, with multiple trial readouts in 2H26 and 2027.
2 months ago · zacks.com
CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue EstimatesCG Oncology, Inc. (CGON) came out with a quarterly loss of $0.9 per share versus the Zacks Consensus Estimate of a loss of $0.7. This compares to a loss of $0.54 per share a year ago.
2 months ago · globenewswire.com
CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business UpdatesDALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.
2 months ago · zacks.com
CG Oncology Stock Gains 12% in Three Months: What's Driving It?CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
3 months ago · marketbeat.com
CG Oncology Eyes Bladder Cancer Breakthrough With Phase 3 Data, Q4 Filing AheadCG Oncology NASDAQ: CGON Chief Executive Officer Arthur outlined the company's upcoming clinical and regulatory milestones for cretostimogene during a presentation at the Goldman Sachs Global Healthcare Conference, emphasizing data readouts, a potential filing and commercial preparation in non-muscle invasive bladder cancer, or NMIBC.
3 months ago · seekingalpha.com
CG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptCG Oncology, Inc. (CGON) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Analyst Summary
Add to Watchlist
Select watchlists to add or remove CGON